Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease

Journal of Health Economics and Outcomes Research
Sue PereraJoanne Brady

Abstract

This retrospective cohort study aimed to describe and quantify healthcare resource utilization and costs for patients with ulcerative colitis (UC) and Crohn's disease (CD) following initiation of biologic therapy. Resource utilization and costs were analyzed at baseline and 1- and 2-years after initiating a biologic. Data were extracted from a US administrative health insurance claims database for adults ≥18 years. Eligible patients were continuously enrolled in a health plan with medical and pharmacy benefits for ≥12 months prior to, and 12 months (primary analysis) or 24 months (secondary analysis) after index date (biologic initiation). In total, 4864 and 2692 patients with UC, and 8910 and 5227 patients with CD were identified in the 1- and 2-year follow-up cohorts, respectively. Of 1-year follow-up cohort patients, 45% received the same biologic initiated at index for ≥1 year. Infliximab and adalimumab were the most commonly initiated biologics in patients with UC or CD. The highest proportion of patients who continued with the same biologic after 1- and 2-years had initiated therapy with infliximab for both indications (although at the 1-year follow-up for CD, the highest proportion continued to use natalizumab, but this ...Continue Reading

References

Jan 14, 2010·The American Journal of Gastroenterology·Asher KornbluthUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Aug 14, 2012·Gastroenterology·Anne F PeeryNicholas J Shaheen
Nov 21, 2012·Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie·Angela RocchiSubrata Ghosh
Feb 18, 2015·Journal of Crohn's & Colitis·R V BryantS P L Travis
Mar 25, 2015·Nature Reviews. Rheumatology·Kazuki YoshidaSeoyoung C Kim
Jun 17, 2015·Canadian Journal of Gastroenterology & Hepatology·Stephanie CowardGilaad G Kaplan
Sep 24, 2015·The Cochrane Database of Systematic Reviews·Katie LeBlancJohn K MacDonald
Sep 24, 2015·Expert Review of Gastroenterology & Hepatology·Jørgen JahnsenPetr Ricanek
Feb 20, 2016·Gut·Jean-Frédéric ColombelBrian G Feagan
Feb 26, 2016·World Journal of Gastrointestinal Pathophysiology·Marcello CintoloWalter Fries
Sep 21, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Julajak LimsrivilaiPeter D R Higgins
Feb 22, 2017·Inflammatory Bowel Diseases·Laura E TargownikCharles N Bernstein
Jun 5, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Kyle D NullPaul Healey
Jul 29, 2017·Alimentary Pharmacology & Therapeutics·M EberhardsonO Olén
Nov 1, 2017·Journal of Gastroenterology and Hepatology·Hiroki TanakaUNKNOWN ADJUST study group
Nov 23, 2017·Alimentary Pharmacology & Therapeutics·H YuK T Park
Apr 4, 2018·The American Journal of Gastroenterology·Gary R LichtensteinBruce E Sands

❮ Previous
Next ❯

Citations

May 22, 2020·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Parambir S DulaiJames Murphy

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies

Software Mentioned

R
Instant

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.